Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Opko Health Rallied 15% Today

By Todd Campbell - Sep 17, 2018 at 4:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are betting that a recent tumble will provide a good buy opportunity.

What happened

After the U.S. Securities and Exchange Commission (SEC) levied charges against Opko Health ( OPK -2.77% ) and billionaire CEO Phillip Frost last week, bargain hunters bid the company's share price up 15% on Monday.

So what

The SEC is suing 10 individuals, including Frost, as well as 10 associated entities, including Frost's Frost Gamma Investments Trust and Opko Health, for participating in "long-running fraudulent schemes that generated over $27 million from unlawful stock sales and caused significant harm to retail investors who were left holding virtually worthless stock."

A wooden gavel sitting on $100 bills spread out on a flat surface.


The charges allege a group of "microcap fraudsters" used "classic pump-and-dump schemes" to accumulate large positions in companies that they later sold at inflated prices following illegal promotional activity. According to the SEC's complaint, Frost participated in two of three schemes orchestrated by the group.

Following the SEC's announcement, the Nasdaq halted trading in Opko Health pending a review of information. The trading halt was lifted last Friday, and investors reacted by flocking to the exits. The sell-off appears to have attracted the attention of bargain-hunters who are betting Opko Health will survive the setback.

OPK Chart

OPK data by YCharts

Now what

Opko Health and Frost have issued separate statements aimed to shore up investor confidence. However, SEC allegations aren't made lightly.

If Opko Health escapes unscathed by the SEC, then investors' attention will return to the company's prospects. Unfortunately, the company's performance lately has been lackluster. Partner Tesaro (NASDAQ: TSRO) walked away from Opko's chemotherapy-induced nausea and vomiting drug, Varubi, earlier this year following concerns over safety. Meanwhile, sales of Opko's hyperparathyroidism treatment, Rayaldee, have been anemic. Despite winning FDA approval in 2016, Rayaldee only had $4.8 million in sales in the second quarter of 2018. The company's lab business has also seen sales slip. Altogether, Opko Health's revenue declined 10% to $263.7 million last quarter.

Overall, Opko is "confident" that this "matter will be resolved favorably for the company," and Frost plans to "fight the charges that have been brought against me and will fight to clear my name," but there's no telling how this shakes out from here.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
$3.86 (-2.77%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.